Cal 1-transduced haematopoietic stem progenitor cells

Drug Profile

Cal 1-transduced haematopoietic stem progenitor cells

Alternative Names: Cal 1 therapy; Cal 1-modified HSPC; Cal-1; CAL-MGMT; LVsh5C46; VIP

Latest Information Update: 14 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Calimmune
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV-1 infections

Most Recent Events

  • 14 Oct 2016 Preclinical trials in HIV-1 infections (Prevention) in USA (IV) before October 2016
  • 06 Sep 2016 Calimmune suspends enrolment in a phase I/II trial for HIV-1 infections in Australia (ACTRN12615000763549)
  • 18 Feb 2016 Phase-I/II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top